Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | ACACA | Q13085 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539605 | 0.88 | RAB9A (0.49) | PPARDPPARAMAOBPRSS1PRSS2 | |
| SCHEMBL6539604 | 0.88 | MEN1 (0.53) | MEN1PABPC1KMT2AACACBACACA | |
| SCHEMBL6540586 | 0.87 | MEN1 (0.54) | MEN1PABPC1KMT2AACACBACACA | |
| SCHEMBL6231187 | 0.84 | MEN1 (0.55) | MEN1PABPC1KMT2AACACBACACA | |
| SCHEMBL6206366 | 0.80 | MEN1 (0.56) | MEN1PABPC1KMT2AACACBACACA | |
| Hydrochloric Acid SCHEMBL6207662 | 0.79 | MEN1 (0.55) | MEN1PABPC1KMT2AACACBACACA | |
| SCHEMBL6539764 | 0.76 | MEN1 (0.50) | MEN1PABPC1KMT2AACACBACACA | |
| SCHEMBL6208425 | 0.76 | MEN1 (0.56) | MEN1PABPC1KMT2AACACBACACA | |
| SCHEMBL6207483 | 0.75 | CTSS (0.52) | MAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL6540335 | 0.74 | RAB9A (0.52) | ACACBMAOBNR4A1NR4A2NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | MEN1 4420/4885PABPC1 2765/4885KMT2A 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.